South Carolina Department of Health and Human Services

Post Office Box 8206 Columbia, South Carolina 29202-8206 www.scdhhs.gov

January 9, 2007

MEDICAID BULLETIN

DEN	07-02	PHY-ER	07-01
HH-HOSP	07-01	PHY-MSP-CBP	07-01
НМО	07-01	PHY-MSP-HBP	07-01
HOS-IP-GEN	07-01	PHY-OPHT	07-01
HOS-IP-IMD	07-02	PHY-PATH	07-01
HOS-IP-RTF	07-02	PHY-PC-FP/GP	07-01
HOS-OP	07-01	PHY-PC-GER	07-01
MC-DHEC	07-01	PHY-PC-INT	07-01
MC-FQHC	07-01	PHY-PC-NEO	07-01
MC-MCHC	07-01	PHY-PC-OG	07-01
MC-RHC	07-01	PHY-PC-PED	07-01
MHRC-ADA	07-01	PHY-PC-PED/SUB	07-01
MHRC-MHC	07-01	PHY-PS	07-01
PHARM	07-01	PHY-RAD	07-01
PHY-ALG	07-01	PHY-S	07-01
PHY-ANES	07-01	PHY-SPEC	07-01
PHY-CARD	07-01	PHY-SURG	07-01
PHY-DERM	07-01	POD	07-01
DUV_ENT	07-01		

TO: **Providers Indicated**

SUBJECTS: I. **Dose Optimization Program**

> S. C. GAPS Program and Medicare Part D Prescription Drug Plans II.

III. **South Carolina Medicaid Preferred Drug List**

I. **Dose Optimization Program**

Beginning with dates of service February 1, 2007, the South Carolina Department of Health and Human Services (DHHS) will implement a Dose Optimization program applicable for Medicaid Pharmacy Services claims. The focus of the Dose Optimization program is improved patient compliance with drug therapy regimens, reduced potential for exceeding the maximum recommended dose as determined by the Food and Drug Administration, and decreased adverse drug events.

Dose Optimization is an enhancement to the current Quantity Limits program (http://southcarolina.fhsc.com/Downloads/provider/QuantityLimits-SCpharmacy.pdf). Medications that may be indicated for once or twice daily dosing will be identified and where clinically applicable, Dose Optimization edits will limit the number of times the medication is dosed. This editing process will not interfere with the total daily dosage of the medication prescribed for the patient. Prescribers are asked to consider appropriate Dose Optimization guidelines when higher strengths of the drug are commercially available. For example, prescriptions authorized for two Aricept® 5 mg tablets daily should instead be authorized for the commercially available Aricept® 10 mg tablet with instructions of one tablet daily.

Pharmacy claims submitted for quantities that exceed the daily dosing limit will deny for NCPDP 76 - Plan Limitations Exceeded. Also, dependent upon the established dosing limitations, additional Dose Optimization messages may include:

- 1.000 Quantity Per Day Exceeded
- 2.000 Quantity Per Day Exceeded
- Quantity of 1.000 Per Week Exceeded

When clinically appropriate, DHHS encourages pharmacy providers to contact prescribers regarding those prescriptions where changes may be appropriate to conform to daily dosing limitations. For those patients who require unique dosing regimens, pharmacy providers should ask the prescriber or the prescriber's designated office personnel to contact the First Health Services Clinical Call Center at 1-866-247-1181 (toll-free) to request prior authorization (PA). Those products subject to Dose Optimization may be found at http://southcarolina.fhsc.com. The Dose Optimization listing will be updated periodically; therefore, providers may find it beneficial to refer to the Web site for the most current information. Appropriate, cost-effective prescribing is encouraged, and the cooperative efforts of health care providers toward the achievement of this objective are greatly appreciated.

II. S. C. GAPS Program and Medicare Part D Prescription Drug Plans

The Gap Assistance Pharmacy Program for Seniors (GAPS) is a state pharmacy assistance program that was established by DHHS in 2006 to supplement Part D drug coverage for South Carolina Medicare beneficiaries who are enrolled in a Prescription Drug Plan (PDP), have an income below 200% of the federal poverty level and do not qualify for the Low Income Subsidy. These Medicare beneficiaries are subject to a lapse in prescription coverage (also known as the doughnut hole) when their drug expenses total a certain dollar amount. Without the GAPS program, the beneficiary is responsible for 100% of the prescription costs during the doughnut hole timeframe. The GAPS benefit, however, provides assistance during this coverage gap by reducing the beneficiary's out-of-pocket costs from 100% to 5%.

To take advantage of the GAPS benefit in calendar year 2007, Medicare beneficiaries who will experience the lapse in prescription coverage should be enrolled in a PDP that participates with DHHS' GAPS program. Following is a listing of the plans that have agreed to participate with GAPS in 2007:

GAPS-Participating Company	Name of Plan	Phone Number For Beneficiaries
Arcadian Health Plan (H5783)	Charleston - Plus (002)	1-800-573-8597
Arcadian Health Plan (H5783)	Charleston - Premier (003)	1-800-573-8597
Arcadian Health Plan (H5783)	Greenville - Plus (006)	1-800-573-8597
Arcadian Health Plan (H5783)	Greenville - Premier (007)	1-800-573-8597
BlueCross BlueShield of SC (S5953)	MedBlue Rx (001)	1-800-930-2836
BlueCross BlueShield of SC (S5953)	MedBlue Rx Plus (002)	1-800-930-2836
Carolina Medicare Prime (S8277)	Carolina Medicare Prime (001)	1-866-624-4790
Community Care Rx [Member Health, Inc.] (S5803)	Community Care Rx Basic (078)	1-888-868-5854
Community Care Rx [Member Health, Inc.] (S5803)	Community Care Rx Choice (146)	1-888-868-5854
Community Care Rx [Member Health, Inc.] (S5803)	Community Care Rx Gold (226)	1-888-868-5854
Coventry Health & Life Insurance Co. (S5670)	AdvantraRx Value (051)	1-800-882-3822
Coventry Health & Life Insurance Co. (S5670)	AdvantraRx Premier (052)	1-800-882-3822

GAPS-Participating Company	Name of Plan	Phone Number For Beneficiaries
First Health Part D (S5768)	First Health Premier (012)	1-800-588-3322
Humana Insurance Co. (S5884)	Humana PDP Standard (067)	1-800-706-0872
Humana Insurance Co. (S5884)	Humana PDP Enhanced (008)	1-800-706-0872
InStil Health Insurance Co. (S5946)	InStil Rx (001)	1-877-446-7845
InStil Health Insurance Co. (S5946)	InStil Rx Plus (003)	1-877-446-7845
WellCare (S5967)	WellCare Signature (043)	1-888-481-5252

III. South Carolina Medicaid Preferred Drug List

The Preferred Drug List (PDL) has been revised to include several additions/deletions of specific drugs within certain PDL therapeutic classes. Attached to this bulletin is a comprehensive listing of products within all therapeutic classes that comprise the PDL. Upon initial implementation of the specified PDL changes, pharmacists will observe soft edits when pharmacy claims are submitted for products that will eventually require prior authorization. This period of soft editing will occur for several weeks. The soft edit will not cause the claim to reject; however, pharmacists are asked to take this opportunity to inform both the prescriber and beneficiary of the eventual PA requirement.

Effective with dates of service January 30, 2007, hard edits will be activated (*i.e.*, pharmacy claims without prior authorization [PA] approval will deny) for newly designated non-preferred products within the therapeutic classes listed below. The **complete PDL** (attached to this bulletin) includes the following changes:

REVISED PDL DRUG CLASSES: Effective January 30, 2007		
1) Second Generation Sulfonylureas		
2) Cholesterol Lowering Agents-Fibric Acids		
3) Glaucoma Therapy - Alpha ₂ Adrenergics		
4) Proton Pump Inhibitors		
5) Insulins		

REVISED PDL DRUGS: Effective January 30, 2007				
PREFERRED		NON-PREFERRED		
SECOND GENERATION SULFONYLUREAS				
Glimepiride	Added to PDL	Amaryl®		
Glipizide	Remains on PDL	Diabeta®		
Glipizide ER	Remains on PDL	Glucotrol®		
Glyburide	Remains on PDL	Glucotrol XL®		
Glyburide Micronized	Remains on PDL	Glynase®		
		Micronase®		
CHOLESTEROL LOWERING AGENTS - FIBRIC ACIDS				
Gemfibrozil	Remains on PDL	Antara®		
Lofibra®	Added to PDL	Lopid®		
Tricor®	Remains on PDL	Triglide®		
GLAUCOMA THERAPY: ALPHA₂ ADRENERGICS				
Alphagan P®	Added to PDL	lopidine®		
Brimonidine Tartrate	Remains on PDL	·		
PROTON PUMP INHIBITORS*				
Nexium®	Remains on PDL	Aciphex®		
Prevacid®	Added to PDL	Omeprazole		
Prilosec OTC®	Remains on PDL	Prilosec®		
		Protonix®		
		Zegerid®		
		riteria in effect for this class. on the PDL will be preferred.		
	INSULII			
Humalog 50/50	Added to PDL	Apidra®		
Humulin 50/50	Remains on PDL	Exubera®		
Lantus®	Remains on PDL	Humalog 75/25®		
Levemir® Vial	Remains on PDL	Humalog®		
Novolin N®	Remains on PDL	Humulin N®		
Novolin R®	Remains on PDL	Humulin R®		
Novolin 70/30®	Remains on PDL	Humulin 70/30®		
Novolog®	Remains on PDL	Levemir® Pen*		
Novolog Mix 70/30®	Remains on PDL			
* Patients established on Levemir® pen therapy are grandfathered. Levemir® pen does not require Prior Authorization for patients on established therapy.				

Prescribers are strongly encouraged to write prescriptions for "preferred" products. However, if a prescriber deems that the patient's clinical status necessitates therapy with a PA-required drug, the prescriber (or his/her designated office personnel) is responsible for initiating the prior authorization request. A prospective, approved PA request will prevent rejection of prescription claims at the pharmacy due to the PA requirement.

Medicaid Bulletin January 9, 2007 Page 5

> All PA requests should be telephoned or submitted by fax to the First Health Clinical Call Center by the prescriber or the prescriber's designated office personnel. The toll-free telephone and fax numbers for the Clinical Call Center are 866-247-1181 and 888-603-7696, respectively. The First Health Clinical Call Center telephone number is reserved for use by healthcare professionals and should not be furnished directly to beneficiaries. [First Health's S. C. Medicaid beneficiary call center telephone number for questions regarding Pharmacy Services-related issues is 800-834-2680; providers may furnish the beneficiary call center telephone number to Medicaid beneficiaries for Pharmacy Services-related issues only.] Questions about Medicare eligibility issues and Part D should be directed to 1-800-MEDICARE.

> A pharmacy claim submitted for a PA-required product that has not been approved for Medicaid reimbursement will reject. If this occurs, the pharmacist should contact the prescriber so that a determination may be made regarding whether a drug not requiring PA is clinically appropriate for the patient.

> Questions regarding this bulletin should be directed to the Department of Pharmacy Services at (803) 898-2876.

> > /s/

Robert M. Kerr Director

RMK/bgam

Attachments

NOTE: To receive Medicaid bulletins by email, please send an email to bulletin@scdhhs.gov indicating your email address and contact information.

To sign up for Electronic Funds Transfer of your Medicaid payment, please go to the following link for instructions: http://www.scdhhs.gov/dhhsnew/serviceproviders/eft.asp

{Non-listed products belonging to therapeutic classes that comprise the PDL require PA}

{Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

ANALGESIC

NSAIDs

Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Etodolac
Fenoprofen
Flurbiprofen
Ibuprofen
Indomethacin

Indomethacin SR Ketoprofen

Ketoprofen ER Ketorolac

Meclofenamate Sod.

Nabumetone Naproxen

Naproxen Sodium

Oxaprozin Piroxicam Sulindac

Tolmetin Sodium

OPIOIDS, EXTENDED RELEASE

Avinza®
Duragesic® Patch
Kadian®
Morphine Sulfate ER*
**Generic MS Contin®

ANTI-INFECTIVE

ANTIBACTERIALS

Cephalosporins, 2nd Generation

Ceftin® Suspension Cefuroxime Tablets Cefzil® Tablets Cefzil® Suspension

Cephalosporins, 3rd Generation

Omnicef® Capsules Omnicef® Suspension Spectracef® Tablets

Macrolides / Ketolides

Biaxin XL®
Clarithromycin
EryPed®
Ery-Tab®
Erythromycin Base
Erythromycin Estolate
Erythromycin Ethylsuc.
Erythromycin Stearate
Erythrocin Stearate
Erythromycin & Sulfisox.
Zithromax®

Quinolones, 2nd and 3rd Generation

Avelox®
Ciprofloxacin
Factive®
Levaquin®
Ofloxacin

ANTIFUNGALS, ORAL

Onychomycosis Agents

Gris-Peg® Griseofulvin Lamisil®

ANTIVIRALS, ORAL

Herpes Antivirals

Acyclovir Famvir® Valtrex®

CARDIOVASCULAR

ACE INHIBITORS (ACEI)

Benazepril
Benazepril/HCTZ
Captopril
Enalapril
Enalapril/HCTZ
Lisinopril
Lisinopril/HCTZ

ACEI, CALCIUM CHANNEL BLOCKER COMBINATIONS

Lotrel® Tarka®

ANGIOTENSIN RECEPTOR BLOCKERS

Avalide®
Avapro®
Benicar®
Benicar HCT®
Cozaar®
Diovan®
Diovan HCT®
Hyzaar®
Micardis®
Micardis HCT®
Teveten
Teveten HCT®

BETA BLOCKERS

Acebutolol Atenolol Atenolol/Chlorthalidone Betaxolol Bisoprolol Fumarate Bisoprolol/HCTZ Labetolol Metoprolol Tartrate Nadolol **Pindolol** Propranolol Propranolol/HCTZ Sotalol Timolol Coreg®* regular release formulation *Use of Coreg® reserved for treatment of hypertension accompanied by heart failure.

CALCIUM CHANNEL BLOCKERS, DIHYDROPYRIDINE

Dynacirc®
Dynacirc CR®
Nicardipine
Nifedical XL®
Nifedipine ER and SA
Norvasc®
Plendil ®

CALCIUM CHANNEL BLOCKERS, NON-DIHYDROPYRIDINES

Cartia XT®
Diltia XT®
Diltiazem
Diltiazem ER and XR
Taztia XT®
Verapamil
Verapamil ER
Verapamil SR

LIPOTROPICS

Bile Acid Sequestering Resins

Cholestyramine
Cholestyramine Light
Colestid®
Welchol®

Fibric Acid Derivatives

Gemfibrozil Lofibra® Tricor®

Niacin Derivatives

Niacor® Niaspan®

Statins Advicor®

Altoprev® Crestor® Lescol ® Lescol XL® Lipitor® Lovastatin Pravastatin Simvastatin



South Carolina Department of Health and Human Services Preferred Drug List

Products Within PDL Therapeutic Classes Are Available Without Prior Authorization (PA)

{Non-listed products belonging to therapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

Cholesterol-Absorption Inhibitors

Vytorin® Zetia®

CENTRAL NERVOUS SYSTEM

ALZHEIMER'S AGENTS

Cholinesterase Inhibitors

Aricept® Exelon® Razadyne®

ANTI-MIGRAINE AGENTS

Selective Serotonin Agonists

Amerge®
Axert®
Imitrex® Tablets,
Imitrex® Injection
Imitrex® Nasal Spray
Maxalt®
Maxalt-MLT®
Relpax®
Zomig® Tablets
Zomig® Nasal Spray

* See the listing at: http://southcarolina.com

for the quantity limits for this class. (Click on Providers, then Documents, then Pharmacy Quantity Limits.)

ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS

Amphetamine Salt
Combination
Dextroamphetamine
Dextroamphetamine SR
Metadate CD®
Metadate ER®
Methylin®

Methylin ER®
Methylphenidate
Methylphenidate SR
Ritalin LA®*
Adderall XR®*
Concerta®*
Focalin®*
Focalin XR®*
* Generic agents
considered "first-line"
when appropriate.

SEDATIVE/HYPNOTICS, NON-BARBITURATES

Temazepam Lunesta®* * Generics should be considered "first-line" when appropriate.

ENDOCRINE AND METABOLIC

ANTI-DIABETICS

Alpha-Glucosidase Inhibitors

Glyset® Precose®

Biguanides

Metformin Metformin ER

Biguanide Combination

ActoPlus Met® Avandamet® Glucovance® Glyburide/Metformin

Insulins

Lantus
Levemir® Vial
Novolin® N
Novolin® R
Novolin® 70/30
Novolog®
Novolog® Mix 70/30
Humalog 50/50
Humulin 50/50

Meglitinides

Starlix®

Sulfonylureas, 2nd Generation

Glimepiride Glipizide Glipizide ER Glyburide Glyburide Micronized

Thiazolidinediones

Actos® Avandia®

BIPHOSPHONATES - OSTEOPOROSIS

Fosamax®

GASTROINTESTINAL

ANTI-EMETICS (ORAL)

Serotonin Receptor Antagonists

Kytril ® Zofran® Zofran ODT®

Histamine-2 Receptor Antagonists

Famotidine Ranitidine Zantac® Syrup

Proton Pump Inhibitors*

Nexium® Prevacid® Prilosec OTC®

* Clinical criteria are in effect for this class. Once criteria are met, the PPI's listed on the PDL are preferred.

GENITOURINARY

ANTISPASMODICS

Detrol LA® Enablex® Oxybutynin Oxytrol ® Sanctura® Vesicare®

IMMUNOLOGICS

IMMUNOMODULATORS, ORAL

Hepatitis C Therapy, Pegylated Interferons

Pegasys® Pegasys® Conv. Pack Peg-Intron® Peg-Intron® Redipen™

Hepatitis C Therapy, Ribavirins

Rebetol ® Ribavirin 200mg tablets

IMMUNOMODULATORS, TOPICAL

Elidel® *
Protopic® *

* Prescribers: Please use these agents as advised by the respective manufacturer and reserve for only those patients who have failed traditional eczema therapy.

{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA}
{Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

OPHTHALMICS

GLAUCOMA THERAPY

Alpha-2 Adrenergics

Brimonidine Tartrate Alphagan P®

Beta Blockers

Betaxolol HCI
Carteolol HCI
Levobunolol HCI
Metipranolol
Timolol Maleate
Timolol Maleate gelforming

Carbonic Anhydrase Inhibitors

Azopt® Cosopt® Trusopt®

Prostaglandin Agonists

Lumigan® Travatan® Xalatan®

RESPIRATORY

ANTI-CHOLINERGICS

Atrovent® Combivent® Spiriva®

ANTIHISTAMINES, 2nd GENERATION AND DECONGESTANT COMBINATIONS

Allegra®
Allegra-D®
Loratadine OTC (Tabs,
Rapid Dissolve, Syrup)
Loratadine-D OTC
Zyrtec® (all
formulations)
Zyrtec D®

BETA ADRENERGIC DEVICES, SHORT-ACTING INHALERS, INHALATION

Albuterol (CFC & HFA) Xopenex® HFA

BETA ADRENERGIC DEVICES, LONG-ACTING METERED DOSE INHALERS

Serevent®*

* Prescribers are reminded of the revised labeling for long acting beta adrenergic agents "These medicines may increase the chance of severe asthma episodes, and death when those episodes occur."

BETA ADRENERGIC AGENTS, SHORT-ACTING NEBULIZERS

Albuterol Metaproterenol Xopenex®*

* Generic agents should be considered as" first-line" therapy when appropriate.

GLUCOCORTICOIDS

Inhaled, Inhalation Devices

Asmanex® Azmacort® Flovent HFA® Qvar®

Intranasal Steroids

Flonase® Nasacort AQ® Nasonex®

Glococorticoids and Long-Acting Beta-2 Adrenergics

Advair® Diskus

* Prescribers are reminded of the revised labeling for long acting beta adrenergic agents "These medicines may increase the chance of severe asthma episodes, and death when those episodes occur."

Leukotriene Receptor Antagonists

Accolate® Singulair®*

* No PA is required if used in the treatment of asthma with inhaled steroid or beta agonist therapy or after trial of a second generation antihistamine or nasal steroid therapy.



{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

ACCOLATE ACEBUTOLOL

ACTOS

ACTOPLUS MET ACYCLOVIR ADDERALL XR ADVAIR DISKUS

ADVICOR

ALBUTEROL (CFC & HFA)
ALBUTEROL NEBULIZER

ALLEGRA
ALLEGRA-D
ALPHAGAN P
ALTOPREV
AMERGE

AMPHETAMINE SALT COMBINATION

ARICEPT ASMANEX ATENOLOL

ATENOLOL/CHLORTHALIDONE

ATROVENT
AVALIDE
AVANDIA
AVAPRO
AVELOX
AVINZA
AXERT
AZMACORT

В

AZOPT

BENAZEPRIL
BENAZEPRIL/HCTZ

BENICAR
BENICAR HCT
BETAXOLOL

BETAXOLOL HCL OPHTHALMIC

BIAXIN XL

BISOPROLOL FUMARATE BISOPROLOL/HCTZ

BRIMONIDINE TARTRATE OPHTH.

C

CAPTOPRIL

CARTEOLOL HCL OPHTHALMIC

CARTIA XT

CEFTIN SUSPENSION
CEFUROXIME TABLETS
CEFZIL SUSPENSION
CEFZIL TABLETS
CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT

CLARITHROMYCN

CIPROFLOXACIN

COLESTID
COMBIVENT
CONCERTA
COREG
COSOPT
COZAAR

CRESTOR

D

DETROL LA

DEXTROAMPHETAMINE SR DICLOFENAC POTASSIUM DICLOFENAC SODIUM

DIFLUNISAL
DILTIA XT
DILTIAZEM
DILTIAZEM ER
DILTIAZEM XR
DIOVAN
DIOVAN
DIOVAN HCT
DURAGESIC PATCH

DYNACIRC CR

E

ELIDEL ENABLEX ENALAPRIL ENALAPRIL/HCTZ

ERYPED ERY-TAB

ERYTHROCIN STEARATE ERYTHROMYCIN BASE ERYTHROMYCIN ESTOLATE

ERYTHROMYCIN ETHYLSUCCINATE

ERYTHROMYCIN STEARATE

ERYTHROMYCIN WITH SULFISOXAZOLE

ETODOLAC EXELON

F

FACTIVE
FAMOTIDINE
FAMVIR
FENOPROFEN
FLONASE
FLOVENT HFA
FLURBIPROFEN
FOCALIN
FOCALIN XR
FOSAMAX

G

GEMFIBROZIL
GLIMEPIRIDE
GLIPIZIDE
GLIPIZIDE ER
GLUCOVANCE
GLYBURIDE

GLYBURIDE MICRONIZED GLYBURIDE/METFORMIN

GLYSET GRISEOFULVIN GRIS-PEG



{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

н

HUMALOG 50/50 HUMULIN 50/50 HYZAAR

IBUPROFEN
IMITREX INJECTION
IMITREX NASAL SPRAY
IMITREX TABLETS
INDOMETHACIN
INDOMETHACIN SR

J

K V DI V V

KADIAN KETOPROFEN KETOPROFEN ER KETOROLAC KYTRIL

L

LABETOLOL
LAMISIL
LANTUS
LESCOL
LESCOL XL
LEVAQUIN
LEVEMIR VIAL

LEVOBUNOLOL HCL OPHTHALMIC

LIPITOR
LISINOPRIL
LISINOPRIL/HCTZ
LOFIBRA

LORATADINE OTC (ALL FORMS)

LORATADINE-D OTC

LOTREL LOVASTATIN LUMIGAN LUNESTA M

MAXALT MAXALT-MLT

MECLOFENAMATE SODIUM

METADATE CD METADATE ER

METAPROTERENOL NEBULIZER

METFORMIN ER
METHYLIN
METHYLIN ER
METHYLPHENIDATE

METHYLPHENIDATE SR

METIPRANOLOL OPHTHALMIC

METOPROLOL TARTRATE

MICARDIS MICARDIS HCT

MORPHINE SULFATE ER

N

NABUMETONE NADOLOL NAPROXEN

NAPROXEN SODIUM NASACORT AQ

NASONEX NEXIUM NIACOR NIASPAN NICARDIPINE NIFEDICAL XL

NIFEDICAL XL NIFEDIPINE ER NIFEDIPINE SA NORVASC NOVOLIN 70/30

NOVOLIN N NOVOLIN R NOVOLOG

NOVOLOG MIX 70/30

0

OFLOXACIN

OMNICEF CAPSULES
OMNICEF SUSPENSION

OXAPROZIN OXYBUTININ OXYTROL

P

PEGASYS

PEGASYS CONVENIENCE PACK

PEG-INTRON

PEG-INTRON REDIPEN

PINDOLOL
PIROXICAM
PLENDIL
PRAVASTATIN
PRECOSE
PREVACID

PRILOSEC OTC PROPRANOLOL

PROPRANOLOL/HCTZ

PROTOPIC

Q

QVAR

R

RANITIDINE RAZADYNE REBETOL RELPAX

RIBAVIRIN TABLETS

RITALIN LA



{Non-listed products belonging to therapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

Listing Updated: January 2007

S

SANCTURA SEREVENT SIMVASTATIN

SINGULAIR

SOTALOL

SPECTRACEF TABLETS

SPIRIVA STARLIX

SULINDAC

T

TARKA TAZTIA XT

TEMAZEPAM

TEVETEN HCT

TIMOLOL

TEVETEN

TIMOLOL MALEATE GEL-FORMING TIMOLOL MALEATE OPHTHALMIC

TOLMETIN SODIUM

TRAVATAN

TRICOR

TRUSOPT

U

V

VALTREX VERAMIL

VERAPAMIL ER VERAPAMIL SR

VESICARE

VYTORIN

W

WELCHOL

X

XALATAN XOPENEX XOPENEX HFA

ZANTAC SYRUP

ZETIA

ZITHROMAX

ZOFRAN

ZOFRAN ODT

ZOMIG

ZOMIG NASAL SPRAY

ZOMIG-ZMT

ZYRTEC (ALL FORMULATIONS)

ZYRTEC D